CompletedNCT00345033
Aripiprazole or placebo added to clozapine for metabolic side effects
About this title
Read the official source — NCT00345033Medication studyAges 18–65United StatesSchizophrenia
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
What did participation involve?
Depending on the group, the protocol specifies the study medication (aripiprazole) or a placebo (an inactive comparison treatment).
- Listed locations
- BostonSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateMarch 2005
- Recruitment status
- Completed
- Enrollment listed in the registry
- 38
- Sponsor
- Massachusetts General Hospital
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00345033
- Official title
Show the full official title
Aripiprazole for Clozapine Associated Medical Morbidity
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Boston
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Massachusetts General Hospital, a hospital or academic medical center.
Did this study involve medication?
Yes. The study involved medication, including Aripiprazole and Placebo.
Who was this study for?
Listed age limits: 18 years to 65 years.
